Role of Interferon-gamma Release Assay for Screening and Monitoring of Latent Tuberculosis Infection in Kidney Transplant Recipients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220720008

Enrollment

100

Registered

2022-07-20

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult kidney transplant recipients TB, isoniazid, immunocompromised

Interventions

All adult kidney transplant recipients will be evaluate by T. SPOT-TB before, at 1 month and 9 months after transplant

Experimental Other

TB immune monitoring

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: All adult kidney transplant recipients

Exclusion criteria

Exclusion criteria: those who are not willing to participate

Design outcomes

Primary

Measure	Time frame
TB-specific immunity 9 months T.SPOT-TB	—

Secondary

Measure	Time frame
TB 9 months PCR	—

Countries

Thailand

Contacts

Public ContactJackrapong Bruminhent

Faculty of Medicine Ramathibodi Hospital, Mahidol University

jackrapong.brm@mahidol.ac.th022011581

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026